ArticleFrontiers in immunology2025
Lung microbiome alterations correlate with immune imbalance in non-small cell lung cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bronchoalveolar lavage microbiota signatures and stage-associated alterations in early-stage and advanced-stage non-small cell lung cancer: a pilot study.Journal of translational medicine · 2026Article
- Functional crosstalk between the lung and eye: a new frontier in chronic lung diseases.Archives of toxicology · 2025Review
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Dual signaling cascade regulating gut-lung axis in Interleukin-6/Interleukin-17 for NSCLC immuno pathogenesis.Frontiers in immunology · 2025Review
- Emerging technologies and current challenges in intratumoral microbiota research.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current understanding of the link between microbiota imbalance and immune function in non-small cell lung cancer (NSCLC) has not been fully elucidated. This study aims to explore the link between dysbiotic lung microbiota and immunity in NSCLC, which may provide valuable information for disease progression monitoring and prognosis prediction. Methods: Lung microbial communities from both the tumor-affected (n = 43) and contralateral healthy sides (n = 38) of lung cancer patients were analyzed by 16S rRNA sequencing. The association between microbial abundance and tumor stages, metastasis or not, nodule size, PD-L1 expression, as well as Ki-67 levels was conducted. Mann-Whitney tests were used to evaluate differences in the systemic immune-inflammation index (SII), T cell subsets (CD3 Results: Significant β-diversity differences were observed between the tumor-bearing and contralateral normal lungs in individuals diagnosed with lung carcinoma. A notable increase in Conclusion: Microbial composition differed significantly between the tumor-affected and healthy sides in lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.